BioNTech
| Institution is active | |
| Legal form | Societas Europaea |
| Founder | Uğur Şahin |
| Founding date | 2008 |
| Headquarters | Mainz, Germany |
| Website | https://biontech.de/ |
Connections
BioNTech
- Investor/shareholder -
Bill & Melinda Gates Foundation
The Bill and Melinda Gates Foundation rose $ 55 million at Biontech in autumn 2019.
BioNTech
-
Sanofi
No information yet.
BioNTech
-
mRNA-Technologie
No information yet.
BioNTech
-
Pfizer
No information yet.
BioNTech
- founder -
Uğur Şahin
No information yet.
BioNTech
- Founder -
Özlem Türeci
No information yet.
BioNTech
- holds shares -
Thomas Strüngmann
Andreas and Thomas Strüngmann took part in the company Biontech founded in 2008 with start-up capital of around $ 180 million.
In July 2020 they were about 50 percent of Biontech.
The rapid increase in Biontech's stock value in 2020 after the development of the COVID 19 vaccine BNT162B2 led to a significant increase in assets of the Strüngmann twins.
In July 2020 they were about 50 percent of Biontech.
The rapid increase in Biontech's stock value in 2020 after the development of the COVID 19 vaccine BNT162B2 led to a significant increase in assets of the Strüngmann twins.
The twins Andreas and Thomas Strüngmann are estimated that around 50% of the shares in Biontech.
BioNTech
- holds shares -
Andreas Strüngmann
Andreas and Thomas Strüngmann took part in the company Biontech founded in 2008 with start-up capital of around $ 180 million.
In July 2020 they were about 50 percent of Biontech.
The rapid increase in Biontech's stock value in 2020 after the development of the COVID 19 vaccine BNT162B2 led to a significant increase in assets of the Strüngmann twins.
In July 2020 they were about 50 percent of Biontech.
The rapid increase in Biontech's stock value in 2020 after the development of the COVID 19 vaccine BNT162B2 led to a significant increase in assets of the Strüngmann twins.
The twins Andreas and Thomas Strüngmann are estimated that around 50% of the shares in Biontech.
BioNTech
- Development and marketing -
Comirnaty (BNT162b2)
No information yet.
BioNTech
- Strategic partnership -
Genentech
No information yet.
BioNTech
- Strategic partnership -
Genmab
No information yet.
BioNTech
- Strategic partnership -
Regeneron Pharmaceuticals
No information yet.
BioNTech
-
Genevant Sciences
No information yet.